AbbVie Expands Portfolio with Acquisition of Apogee Therapeutics
In a notable move within the biotech sector, AbbVie has completed the acquisition of Apogee Therapeutics, reflecting a renewed interest in mergers and acquisitions in the industry.
Editorial Staff
1 min read
Updated 1 day ago
AbbVie has finalized its acquisition of Apogee Therapeutics, marking a significant development in the biotech landscape.
This deal is seen as part of a broader resurgence in biotech mergers and acquisitions, suggesting a revitalization of activity in the sector.
Additionally, results from the Phase 3 trials of a therapy involving LSD are expected, which may further impact the market.
Updates
Update at 13:21 UTC on 2026-06-22
STAT reported AbbVie buys Apogee Therapeutics, LSD therapy Phase 3 results, and more biotech news from The Readout.
Sources: STAT